Eli Lilly and Company, Pfizer, Vertex Pharmaceuticals, Johnson & Johnson, Merck & Co., Inc., Regeneron Pharmaceuticals, and AbbVie are the seven Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical stocks are shares of companies involved in discovering, developing, manufacturing, or selling prescription and over-the-counter medicines. For stock market investors, these stocks represent ownership in the pharmaceutical sector and may offer growth or dividend potential, but they can also be affected by clinical-trial results, regulatory decisions, patent expirations, pricing pressures, and competition. These companies had the highest dollar trading volume of any Pharmaceutical stocks within the last several days.
Eli Lilly and Company (LLY)
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
Shares of NYSE:LLY traded up $9.10 during trading hours on Tuesday, hitting $1,420.09. The stock had a trading volume of 1,040,120 shares, compared to its average volume of 2,938,932. Eli Lilly and Company has a 1-year low of $850.51 and a 1-year high of $1,449.68. The firm has a market capitalization of $1.34 trillion, a price-to-earnings ratio of 46.12, a PEG ratio of 1.73 and a beta of 0.40. The stock's fifty day simple moving average is $1,200.81 and its 200 day simple moving average is $1,094.25. The company has a debt-to-equity ratio of 1.41, a quick ratio of 1.00 and a current ratio of 1.35.
Read Our Latest Research Report on LLY
Pfizer (PFE)
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Shares of PFE traded down $0.20 during midday trading on Tuesday, reaching $30.47. 22,310,020 shares of the stock were exchanged, compared to its average volume of 39,636,875. The company has a market cap of $173.65 billion, a price-to-earnings ratio of 40.03, a P/E/G ratio of 2.00 and a beta of 0.32. The firm has a 50 day simple moving average of $28.60 and a 200-day simple moving average of $26.82. The company has a quick ratio of 0.96, a current ratio of 1.27 and a debt-to-equity ratio of 0.71. Pfizer has a 12-month low of $23.62 and a 12-month high of $31.06.
Read Our Latest Research Report on PFE
Vertex Pharmaceuticals (VRTX)
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.
VRTX traded down $19.05 during trading on Tuesday, hitting $534.10. The stock had a trading volume of 1,204,990 shares, compared to its average volume of 1,388,479. The company has a 50 day simple moving average of $523.32 and a 200-day simple moving average of $479.96. The firm has a market cap of $135.56 billion, a PE ratio of 31.06, a P/E/G ratio of 2.54 and a beta of 0.28. Vertex Pharmaceuticals has a 12 month low of $403.16 and a 12 month high of $568.67.
Read Our Latest Research Report on VRTX
Johnson & Johnson (JNJ)
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
Shares of NYSE:JNJ traded down $2.97 during trading on Tuesday, hitting $267.59. 1,996,987 shares of the stock were exchanged, compared to its average volume of 7,933,802. The company's fifty day simple moving average is $265.74 and its 200-day simple moving average is $247.22. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.74 and a current ratio of 1.02. The company has a market capitalization of $644.17 billion, a price-to-earnings ratio of 40.58, a price-to-earnings-growth ratio of 2.68 and a beta of 0.22. Johnson & Johnson has a 1-year low of $185.12 and a 1-year high of $282.02.
Read Our Latest Research Report on JNJ
Merck & Co., Inc. (MRK)
Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.
Merck & Co., Inc. stock traded down $3.70 on Tuesday, hitting $144.66. The company's stock had a trading volume of 3,273,050 shares, compared to its average volume of 10,633,587. The firm has a market cap of $356.90 billion, a P/E ratio of 149.00, a price-to-earnings-growth ratio of 6.49 and a beta of 0.21. The company has a quick ratio of 1.10, a current ratio of 1.32 and a debt-to-equity ratio of 1.22. The company has a fifty day moving average price of $146.82 and a 200-day moving average price of $126.89. Merck & Co., Inc. has a one year low of $82.01 and a one year high of $156.92.
Read Our Latest Research Report on MRK
Regeneron Pharmaceuticals (REGN)
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.
Shares of NASDAQ:REGN traded up $8.42 during midday trading on Tuesday, reaching $969.68. 466,137 shares of the company's stock were exchanged, compared to its average volume of 824,657. The company's 50 day simple moving average is $795.85 and its two-hundred day simple moving average is $739.07. The firm has a market capitalization of $99.83 billion, a PE ratio of 21.43, a price-to-earnings-growth ratio of 1.37 and a beta of 0.16. Regeneron Pharmaceuticals has a 12 month low of $591.52 and a 12 month high of $974.36. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.78 and a current ratio of 3.34.
Read Our Latest Research Report on REGN
AbbVie (ABBV)
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.
ABBV traded down $0.05 during midday trading on Tuesday, reaching $288.79. 1,509,982 shares of the company's stock were exchanged, compared to its average volume of 6,318,784. The business has a 50-day simple moving average of $269.81 and a two-hundred day simple moving average of $237.57. The firm has a market capitalization of $510.24 billion, a price-to-earnings ratio of 49.76, a price-to-earnings-growth ratio of 1.31 and a beta of 0.24. AbbVie has a one year low of $190.75 and a one year high of $298.74.
Read Our Latest Research Report on ABBV
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Eli Lilly and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.
While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
